T1	outcome 1405 1408	PFS
T2	outcome 1497 1510	TP53 mutation
T3	outcome 1560 1579	FGFR1 amplification
T4	outcome 1122 1125	PFS
T6	total-participants 747 750	459
T8	intervention-participants 585 588	347
T9	control 593 617	placebo plus fulvestrant
T10	control-participants 623 626	174
T11	intervention 55 94	Fulvestrant With or Without Palbociclib
T7	eligibility 631 712	patients with endocrine-pretreated estrogen receptor-positive (ER+) breast cancer
